1. |
Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma[J]. Discov Med, 2013, 15(81):93-100.
|
2. |
Touitou V, Lehoang P, Bodaghi B. Primary CNS lymphoma[J]. Curr Opin Ophthalmol, 2015, 26(6):526-533. DOI:10.1097/ICU.0000000000000213.
|
3. |
Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma:a report from an international primary central nervous system lymphoma collaborative group symposium[J]. Oncologist, 2011, 16(11):1589-1599.DOI:10.1634/theoncologist.2011-0210.
|
4. |
Grimm SA, Pulido JS, Jahnke K, et al. Primary intraocular lymphoma:an international primary central nervous system lymphoma collaborative group report[J]. Ann Oncol, 2007, 18(11):1851-1855. DOI:10.1093/annonc/mdm340.
|
5. |
Fishbume BC, Wilson DJ, Rosenbaum JT, et al. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma[J]. Arch Ophthalmol, 1997, 115(9):1152-1156.
|
6. |
Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma:10 years of experience[J]. Br J Ophthalmol, 2008, 92(3):383-388. DOI:10.1136/bjo.2007.127928.
|
7. |
Riemens A, Bromberg J, Touitou V, et al. Treatment strategies in primary vitreoretinal lymphoma:a 17-center European collaborative study[J]. JAMA Ophthalmol, 2015, 133(2):191-197. DOI:10.1001/jamaophthalmol.2014.4755.
|
8. |
Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement[J]. Ophthalmology, 2002, 109(9):1709-1716.
|
9. |
Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma[J]. Arch Ophthalmol, 2001, 119(10):1518-1524.
|
10. |
Gorovoy I, Prechanond T, Abia M,et al.Toxic corneal epitheliopathy after intravitreal methotrexate and its treatment with oral folic acid[J].Cornea,2013,32(8):1171-1173. DOI:10.1097/ICO.0b013e3182910106.
|